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Abstract
Background: Fatty acid (FA)-alterations may mediate the mutual association between Major Depressive Disorder
(MDD) and cardiovascular disease (CVD). However, etiology of observed FA-alterations in MDD and CVD remains
largely unclear. An interesting candidate may be a mutation in the fatty acid–binding protein 2 (FABP2)-gene,
because it regulates dietary FA-uptake. Therefore, we aimed to test the hypotheses that in MDD-patients the FABP2
Ala54Thr-polymorphism would be (I) more prevalent than in sex- and age-matched controls, (II) associated with
observed alterations in FA-metabolism, and (III) associated with CVD-risk factor waist circumference.
Methods: We measured concentrations of 29 different erythrocyte FAs, FABP2-genotype, and waist circumference
in recurrent MDD-patients and matched never-depressed controls.
Results: FABP2-genotype distribution did not significantly differ between the 137 MDD-patients and 73 matched
controls. However, patients with the Ala54Thr-polymorphism had (I) higher concentrations of especially eicosadienoic
acid (C20:2ω6; P=.009) and other 20-carbon FAs, and associated (II) lower waist circumference (P=.019). In
addition, FABP2-genotype effects on waist circumference in patients seemed (I) mediated by its effect on C20:2ω6,
and (II) different from controls.
Conclusions: Although Ala54Thr-polymorphism distribution was not associated with recurrent MDD, our results
indicate that FABP2 may play a role in the explanation of observed FA-alterations in MDD. For Ala54Thr-
polymorphism patients, potentially adaptive conversion of increased bioavailable dietary precursors into
eicosadienoic acid instead of arachidonic acid might be related to a low waist circumference. Because this is the first
investigation of these associations, replication is warranted, preferably by nutrigenetic studies applying lipidomics and
detailed dietary assessment.
Citation: Mocking RJT, Lok A, Assies J, Koeter MWJ, Visser I, et al. (2013) Ala54Thr Fatty Acid-Binding Protein 2 (FABP2) Polymorphism in Recurrent
Depression: Associations with Fatty Acid Concentrations and Waist Circumference. PLoS ONE 8(12): e82980. doi:10.1371/journal.pone.0082980
Editor: Thierry Alquier, CRCHUM-Montreal Diabetes Research Center, Canada
Received July 31, 2013; Accepted October 29, 2013; Published December 10, 2013
Copyright: © 2013 Mocking et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study has been made possible due to financial aid of the Netherlands Foundation for Mental Health, Utrecht and the Health Research
Development Council, Department Prevention Program (ZonMw). HGR is supported by a NWO/ZonMw VENI-Grant #016.126.059. The funders had no role
in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: R.J.Mocking@amc.uva.nl
☯ These authors contributed equally to this work.
Introduction
Major depressive disorder (MDD) - in particular its recurrent
form (MDD-R) - is a major cause of disability and excess
mortality worldwide [1]. The leading cause of this excess
mortality in MDD is cardiovascular disease (CVD) [2].
Accordingly, the primary CVD-risk factor waist circumference -
reflecting abdominal obesity and insulin resistance - is strongly
associated with MDD [3–7]. Improved understanding of
mechanisms underlying the MDD-CVD relationship might lead
to novel life-prolonging (preventive) treatment strategies.
An important mechanism underlying the MDD-CVD
relationship may be fatty acid (FA)-metabolism, because it
regulates e.g. inflammation, thrombosis and neurotransmitter-
signaling [8–10]. FA-composition of cell membranes is altered
in both MDD and CVD, with decreased ω3 polyunsaturated
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fatty acids (PUFAs) and increased ω6/ω3 PUFA ratios, e.g.
increased arachidonic acid (C20:4ω6; ARA) relative to
eicosapentaenoic acid (C20:5ω3; EPA) [8,11–13]. We
corroborated these findings in a sample of 137 MDD-R
patients, and extended them by showing additional changes in
other FA-classes, e.g. lower overall FA-unsaturation, -chain
length and -peroxidation [14,15]. However, etiology of FA-
alterations in MDD and CVD remains largely unclear.
FA-metabolism is influenced by many different factors,
including genotype [16], dietary intake (e.g. essential ω3 FAs
from fatty fish), lifestyle (physical activity, smoking), and
hormonal regulation [14,17]. Interestingly, we previously
reported that FA-alterations in MDD-R follow a bimodal
distribution [18]. Instead of being unimodally distributed, with
regard to FA-alterations, MDD-R-patients seemed to consist of
two separate groups reflected by two unimodal distributions, a
phenomenon also observed in schizophrenia [19]. This implies
a dichotomous causal factor that divides patients in two groups
and thereby underlies these bimodally distributed FA-
alterations [19]. A possible example of such a dichotomous
causal factor may be a mutation in a gene involved in FA-
metabolism.
An interesting location for such a mutation may be the fatty
acid–binding protein 2 (FABP2) gene. FABP2 is mainly
expressed in small intestine enterocytes, where it is
responsible for uptake of dietary FAs. A transition G to A at
FABP2-codon 54 results in an alanine (Ala) to threonine (Thr)
amino acid substitution (Ala54 to Thr54) [20]. This single
nucleotide polymorphism is common, with a Thr54 allelic
frequency of 30% in most populations, resulting in altered
FABP2 FA-affinity. Homozygous Thr54-carriers show altered
dietary FA-uptake, with increased postprandial concentrations
of 14–18-carbon fatty acids [21]. Because of the
(patho)physiological role of FAs in metabolism, this altered FA-
uptake has been suggested to explain the association of
FABP2 with increased insulin resistance and FA-oxidation,
supporting observations suggesting a role of the FABP2
Ala54Thr-polymorphism in CVD-etiology (e.g. increased waist
circumference and atherosclerosis) [21–25].
Considering this involvement of FABP2 in FA-metabolism,
the FABP2 Ala54Thr-polymorphism may also be particularly
interesting in the explanation of FA-metabolism alterations in
MDD-R patients, because - as stated above - we observed (I)
increased concentrations of 14–18-carbon FAs of several FA-
subclasses [14], and (II) highly significantly lower overall FA-
chain length [15], which was (III) bimodally distributed [18].
Surprisingly, previous studies in healthy and CVD-populations
found no consistent associations of FA-concentrations with the
FABP2 Ala54Thr-polymorphism [24,26,27]. This may be
because, to our knowledge, not all members of the different
FA-subclasses (e.g. long chain saturated and
monounsaturated FA’s) were studied, especially not in a
specific psychiatric (e.g. depressed) population with known
bimodally distributed FA-alterations.
Therefore, the aim of the present study was to test the
hypotheses that in MDD-R-patients the Thr54-polymorphism in
the FABP2-gene would be (I) more prevalent than in sex-and
age-matched controls, (II) associated with observed (bimodally
distributed) alterations in FA-metabolism, and (III) associated
with CVD-risk factor waist circumference.
Materials and Methods
2.1. Ethics Statement
All participants provided written informed consent prior to
enrolment. The ethics committee of the Academic Medical
Center of the University of Amsterdam approved the study.
2.2. Subjects
The current study was part of the DELTA-study, a
randomized clinical trial on the effect of an 8-week cognitive
therapy on MDD-recurrence, described previously [28,29]. This
trial has been registered in the ISRCTN registry as
ISRCTN68246470. As part of DELTA-study’s 2-year follow-up
measurements, we invited subjects to participate in the current
study. At the start of the DELTA-study, participants had to (I)
be aged between 18 and 65, (II) have had ≥2 previous major
depressive episodes in the last five years, and (III) be in
remission of MDD. Exclusion criteria were current or previous
mania or hypomania, any psychotic disorder, alcohol or drug
abuse, and predominant anxiety disorder. Since any form of
therapy (e.g. antidepressant-use) was no inclusion or exclusion
criterion for the trial, the DELTA-sample can be considered
representative for MDD-R patients with respect to this
characteristic.
In addition to the MDD-R patient sample, we recruited age-
and gender- matched healthy control subjects, without a
personal and/or family history of MDD, as described previously
[14].
2.3. Measurements
We took 20ml blood by venipuncture from subjects in the
nonfasting state. As a model of brain FA-concentrations, we
used washed erythrocytes, stored at −80 °C until analyses by
capillary gas chromatography, as described previously [14].
This resulted in data on 29 different FAs, expressed in
pmol/106 erythrocytes [15]. We operationalized FA-metabolism
in two steps. First we tested five main FAs: linoleic acid,
arachidonic acid, α-linolenic acid, eicosapentaenoic acid and
docosahexaenoic acid, together with three indices which
describe overall FA-characteristics: the Unsaturation (UI),
Peroxidation (PI) and Chain Length Indices (CLI) [15,30].
Subsequently, we exploratively tested 24 other FAs. This
approach reduces the multiple testing problem, because it
guides interpretation of effects as explorative or a priori
selected [15,31].
DNA was isolated from blood using a filter-based method
(QIAamp DNA Mini Kit, Qiagen Ltd, United Kingdom).
Polymerase chain reaction (PCR) primers were designed using
Primer 3. PCR primer sequence
TGACAATTTGAAGCTGACAATTA and
AATCAAGAATGCATTGCTCAT, PEX primer sequence bioAT
AAA TTC ACA GTC (L)AA GAA TCA AGC. Genotyping was
done using a Matrix Assisted Laser Desorption Ionization Time
Of Flight (MALDI-TOF) mass spectrometer from Bruker
Fatty Acid-Binding Protein in Recurrent Depression
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Daltonics [32]. All samples were genotyped in duplicate to
increase reliability. Genotyping error rate based on these
duplicates was 3.7%. We operationalized FABP2-genotype in
three categories: GG homozygous, AG heterozygous and AA
homozygous. An A-allele results in the Thr54-polymorphism.
We determined waist circumference in centimeters using a
standard operating procedure [3,4].
2.4. Statistical analyses
2.4.1. Missing data.  We used multiple imputation to prevent
bias possibly introduced by missing or non-detectable FA- or
genotype-data, which resulted in 5 imputed datasets as
described previously [15,33].
2.4.2. Hardy-Weinberg Equilibrium (HWE).  We tested
deviations from HWE separately in patients and controls using
an online calculator χ2-test, available on http://www.oege.org/
software/hwe-mr-calc.html.
2.4.3. Subject characteristics.  We compared patients’ and
controls’ subject characteristics using χ2-tests or independent
Student’s t-tests as appropriate.
2.4.4. Hypotheses testing.  For the first hypothesis, we
used χ2-tests to test whether the distribution of observed
genotype frequencies for patients and controls differed from
expected frequencies. In order to test the association of the
Thr54-polymorphism with the bimodally distributed FA-
alterations in MDD-R-patients (2nd hypothesis), we used linear
mixed models with genotype as predictor variable and a FA-
concentration as outcome variable [34]. In case the overall F-
test for a given FA was significant, we reported parameter
estimates for the distinct genotypes with GG as reference
category. For the association of Thr54-polymorphism with
CVD-risk (3rd hypothesis), we applied a similar model, except
that we entered waist circumference as outcome variable. We
performed no correction for confounders, because these
effects concern genetic effects and genotype is not expected to
be subject to confounding factors.
In addition, we planned several post-hoc tests. First, in case
FA-alterations would show linear associations with FABP2
genotype, e.g. GG: lowest value, AG: middle value, AA, highest
value, we would test the effect of FABP2 on FA-alterations in
linear mixed models with FABP2 recoded as scale variable as
predictor variable and the FAs as outcome variable. Second, if
FA-concentrations and waist circumference would be
associated with FABP2-genotype, we would test correlations
between these FA-alterations and waist circumference. If these
alterations would be significantly correlated, in order to
distinguish the direction of these effects, we would perform
mediation analyses. To this end, we would use linear mixed
models, first with FABP2 and waist circumference as predictor
variables and the FA as outcome variable, subsequently with
FABP2 and the FA as predictor variables and waist
circumference as outcome variable. If the effect of FABP2 on
the FA or waist circumference would disappear after inclusion
of the other factor (the FA or waist circumference) in the model,
this would imply that this other factor mediates the influence of
FABP2. Finally, third, if FABP2 would affect FA-concentrations
or waist circumference in the MDD-patients, we would test
whether this effect would differ from the effect in the matched
controls. In order to test this, we would build another set of
linear mixed models with FABP2 and patients-status (patient or
control) and their interaction (FABP2×patient-status) as
predictor variables and the FA or waist circumference as
outcome variable. Because the patient-status factor in these
models may be subject to confounding, in contrast to the
genetic FABP2-factor, we corrected observed effects for
possibly confounding differences between patients and controls
in age, sex, marital status, educational level, social class,
ethnicity, 17-item Hamilton depression rating scale (HDRS)-
score, and smoking. To prevent losing power, we used
propensity scores, which enable correction for multiple
potentially confounding factors while retaining power.
Propensity scores represent for each case the saved predicted
probability of being a patient or a control, which we calculated
using a binary logistic model with patient-status as dependent,
and the chosen potential confounders as predictor variables.
Although often not dealt with in FA-research, the multitude of
FAs makes multiple comparisons inherent in investigating FA-
metabolism, potentially causing type-I errors [15]. To reduce
this problem we (I) applied pathophysiologically driven data
reduction using the UI, CLI and PI (10), and (II) a priori
designated several outcomes as hypothesis based, and others
as explorative. Although still subject to debate, Bender and
Lange (2001) suggest to perform correction for multiple testing
primarily in confirmatory studies, while explorative results
should be clearly indicated as such [31]. In line with their
advice, and because e.g. Bonferroni correction likely would be
too strict considering the relatively strong assumed correlations
between the different outcomes in this study and therefore may
induce type-II errors, we consequently chose to correct neither
the results of the a priori hypothesized outcomes, nor the
explorative results, for multiple comparisons [31]. Therefore,
particularly the explorative results of this first investigation of
associations between FABP2 and several FAs - particularly in
a psychiatric population - should be interpreted as such.
2.4.5. Power analyses.  We performed sensitivity power
analyses. With power=.80 and two-sided alpha=.05, we were
able to detect effects with a small effect size
(w>0.214;f>0.216;f2>0.080) for all analyses, except for the
differences between the different genotype classes in FA-
measures and waist circumference in the patient group, for
which we were able to detect medium effect sizes (f>0.268).
2.4.6. Software.  We performed multiple imputation using
the package Amelia II, implemented in R [33]. We performed
analyses using SPSS Statistics v.20 (IBM). For multiple
imputation results that are not pooled by SPSS, we used
Rubin’s rules [35]. For the linear mixed models, these were
implemented in a macro available at http://
www.amcpsychiatrie-depressie.nl/cms/downloadfile.asp, as
described previously. We used G*Power 3.1.3 (Kiel, Germany)
to perform power calculations.
Results
3.1. Included sample and missing data
The inclusion procedure resulted in 137 patient and 73
control participants. Of these subjects, 8 patients and 3
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controls had no valid FABP2-genotype due to technical
reasons. Missingness in FA-data has been described
previously [15]. Standard diagnostics by Amelia II suggested
successful imputation.
3.2. Subject characteristics
FABP2-genotype was in HWE in controls (P>.05). Equal sex
and age distributions among patients and controls indicate
successful matching (P>.05). Patients had lower educational
level (P<.001) and greater waist circumference (P=.025) (Table
S1).
3.3. FABP2-distribution in patients and controls
The distribution of FABP2-genotype did not differ among
patients and controls (P=.627). In patients, genotype
frequencies were GG: 57.7%, AG: 34.3%, and AA: 8.0%, and
in controls 50.7%, 41.6%, and 7.7%, respectively.
3.4. Association FABP2-FA-concentrations
Regarding the association of the Thr54-polymorphism with
FA-metabolism, MDD-R patients’ FA-concentrations of the a
priori selected five main FAs and three indices did not differ
according to FABP2-genotype (Table 1). In the explorative
analyses of the other FAs, two FA-concentrations were
significantly associated with FABP2-genotype: eicosadienoic
acid (C20:2ω6; F2,222.6=4.801,P=.009) and docosadienoic acid
(C22:2ω6; F2,289.1=3.271,P=.039; Table 1). Looking at the
parameter estimates for the three subgroups, the AA-genotype
had higher eicosadienoic acid (b=0.437,SEb=0.156,t=7.886,P=.
006) and docosadienoic acid-concentrations
(b=0.236,SEb=0.120,t=2.324,P=.020) compared to the
reference GG-category (Figure 1).
3.5. Association FABP2-waist circumference
Considering the third hypothesis, MDD-R patients’ waist
circumference significantly differed according to FABP2-
genotype (F2,896,6=4.000,P=.019). AA-genotype was associated
with lower waist circumference estimate compared to the
reference GG category (b=-12.243,SEb=4.474,t=-2.737,P=.006;
Figure 2, Panel A).
3.6. Post-hoc analyses
3.6.1. Tests for linear FABP2–FA-associations.  In the
analyses of the association of the Thr54-polymorphism with
FA-metabolism, we observed that while overall effect of
genotype was not significant, parameter estimates for specific
genotypes on some FAs were significant (P<.05) and
suggested a linear associations of FA-concentrations across
FABP2 genotype, e.g. GG: lowest value, AG: middle value, AA,
highest value. This affected especially FAs with a 20-carbon
chain length. We therefore tested this linear relationship using
linear mixed models with FABP2-genotype recoded as a scale
variable (GG=1, AG=2, AA=3). These models showed
significant linear effects of FABP2-genotype on C20
(b=0.106,SEb=0.052,t135=2.032,P=.045), C20:2ω6
(b=0.182,SEb=0.062,t135=2.944,P=.004), and C20:1ω9
(b=0.099,SEb=0.049,t135=2.001,P=.046; Figure 1).
3.6.2. Relationship FABP2, FA-concentrations, and waist
circumference.  In order to disentangle FABP2’s effects on
FA-concentrations and waist circumference, we performed
correlation-analyses between waist circumference and FA-
concentrations, and mediation analyses concerning the effect
of FABP2 on FA-concentrations and waist circumference. In
line with the effects of FABP2-genotype on both eicosadienoic
acid and waist circumference, a post-hoc Pearson’s correlation
test showed that eicosadienoic acid (r=-.243, P=.005) was
significantly negatively correlated with waist circumference in
patients. Subsequently, in a linear mixed model with both
FABP2-genotype and waist circumference as predictors of
eicosadienoic acid, we observed that both FABP2
(F2,317.47=3.285,P=.039,bAA vs.
GG=0.362,SEb=0.155,t173.915=2.342,P=.020) and waist
circumference (F1,3184.09=4.790,P=.
029,b=-0.006,SEb=0.003,t3184.09=-2.189,P=.029) independently
predicted eicosadienoic acid concentrations (overall
F3,799.79=4.890,P=.002). However, the other way around, the
predictive effect of FABP2 on waist circumference lost
significance (P=.102) after including eicosadienoic acid as a
[significant (P=.031)] predictor in the model. This indicates that
FABP2’s effect on waist circumference is mediated by its effect
on eicosadianoic acid, i.e. FABP2’s effect on waist
circumference seems to consist of higher eicosadienoic acid
concentrations in A-allele carriers which on their turn result in
lower waist circumference.
3.6.3. Interactions between patient-status and FABP2 on
C20:2ω6 and waist circumference.  To test whether the
relation between FABP2 and C20:2ω6 and waist circumference
differed between patients and controls, we performed linear
mixed models with patient-status (yes/no) and FABP2-
genotype (GG/AG/AA) and their interaction as predictor
variables, and C20:2ω6 or waist circumference as outcome
variables. There was no patient-status×FABP2-genotype
interaction for C20:2ω6 (F2,882,788=1.069, P=.344). For waist
circumference, the interaction was also non-significant
(F2,640,047=2.055, P=.129), but the patient×AA-genotype
parameter estimate was significant at trend level
(b=-15.140,SEb=7.719,t3184.09=-1.961,P=.051), suggesting that
in patients AA-genotype was associated with a relatively lower
waist circumference compared to controls (Figure 2, Panel A
and B). After correction - using propensity scores - for possibly
confounding differences between patients and controls in e.g.
educational level, social class, HDRS-score, and smoking, the
overall genotype effect remained non-significant
(F2,477,338=2.129, P=.120). However, the patient×AA-genotype
parameter estimate now just gained significance
(b=-15.681,SEb=7.946,t242.59=-1.974,P=.050).
Discussion
4.1. Summary of results
In the present paper, we examined FABP2’s role in MDD-R,
and particularly its relation with bimodally distributed FA-
alterations and CVD-risk factor waist circumference. FABP2
Ala54Thr-polymorphism distribution did not differ between 137
patients with recurrent MDD and 73 matched healthy controls
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without an MDD-history. However, A-allele carrying MDD-R
patients had (I) higher concentrations of several 20-carbon
FAs, especially eicosadienoic acid (C20:2ω6), and associated
(II) lower waist circumference. In addition, post-hoc analyses
suggested that effects of FABP2 on waist circumference in
patients (I) were mediated by its effect on C20:2ω6, and (II)
were different from controls.
4.2. FABP2 genotype distribution
Although it is increasingly recognized that FA-metabolism
may play an important role in psychiatric disease, this is – to
the best of our knowledge – the first investigation of the role of
FABP2 in a psychiatric population. Contrary to our first
hypothesis, genotype distribution did not differ from matched
controls. This may imply that the Ala54Thr-polymorphism plays
no role in vulnerability for MDD-R, as opposed to what have
been suggested for other disorders including obesity and
atherosclerosis [21–25].
4.3. Association between FABP2 and FA-metabolism
However, with regard to our second hypothesis, although the
earlier observed bimodally distributed FA-metabolism
parameters [18] were not associated with the Ala54Thr-
polymorphism, we observed specific associations of the A-
allele with the biologically mutually related FAs eicosadienoic
acid (C20:2ω6) and its elongation product docosadienoic acid
Table 1. Differences in fatty acid concentrations, fatty acid indices and waist circumference between GG, AG and AA-
carriers of the Ala54Thr fatty acid-binding protein 2 (FABP2) polymorphism, vertically graphically divided in a priori (upper
panel) and explorative (lower panel) tests.
 GG (N=79)a AG (N=47)a AA (N=11)a F-value Df1 Df2 P-value
C18:2n6 65.42±1.528 67.05±1.922 65.64±4.198 0.215 2 87.502 .807
C20:4n6 71.07±0.976 73.51±1.374 71.78±2.819 1.003 2 44.068 .375
C18:3n3 0.826±0.036 0.845±0.044 0.848±0.091 0.073 2 163.23 .930
C20:5n3 3.381±0.188 3.278±0.270 3.381±0.534 0.049 2 56.873 .952
C22:6n3 15.19±0.558 14.63±0.844 14.16±1.535 0.287 2 38.681 .752
PI 1.101±0.012 1.096±0.016 1.107±0.031 0.057 2 106.47 .945
CLI 18.31±0.023 18.30±0.030 18.38±0.065 0.601 2 164.04 .549
UI 1.290±0.009 1.289±0.012 1.305±0.023 0.187 2 125.27 .830
WC 91.40±1.556 88.04±2.010 79.16±4.173 4.000 2 896.61 .019
C14 3.333±0.116 3.287±0.154 2.817±0.351 1.047 2 83.660 .355
C16 162.8±2.597 165.5±3.300 157.9±7.915 0.466 2 90.552 .629
C18 103.0±1.206 104.6±1.554 100.4±3.338 0.761 2 295.71 .468
C20 2.490±0.042 2.597±0.054 2.705±0.132 1.965 2 46.139 .152
C22 7.568±0.190 7.481±0.234 8.287±0.501 1.085 2 120.20 .341
C24 14.78±0.496 14.64±0.653 16.40±1.378 0.727 2 84.733 .486
C18:4n3 0.221±0.028 0.280±0.037 0.246±0.078 0.777 2 133.36 .462
C22:5n3 8.009±0.196 7.913±0.251 7.918±0.543 0.048 2 87.828 .953
C18:3n6 0.583±0.026 0.589±0.030 0.479±0.083 0.906 2 24.758 .417
C20:3n6 8.879±0.284 8.796±0.376 9.738±0.887 0.536 2 40.268 .589
C22:4n6 10.46±0.310 10.67±0.409 11.64±0.848 0.883 2 153.36 .416
C22:5n6 1.695±0.070 1.738±0.095 1.777±0.179 0.126 2 62.253 .882
C20:2n6 1.243±0.049 1.377±0.065 1.680±0.148 4.801 2 222.65 .009
C22:2n6 0.509±0.036 0.470±0.050 0.745±0.098 3.271 2 289.13 .039
C14:1n5 0.288±0.036 0.308±0.044 0.286±0.110 0.055 2 40.243 .947
C16:1n7 3.181±0.172 3.068±0.262 2.986±0.521 0.099 2 40.381 .906
C18:1n7 7.469±0.169 7.651±0.246 7.162±0.533 0.403 2 38.358 .671
C20:1n7 0.254±0.029 0.304±0.038 0.261±0.100 0.443 2 41.976 .645
C16:1n9 0.798±0.149 1.124±0.204 1.078±0.543 0.730 2 13.743 .500
C18:1n9 74.61±1.183 74.92±1.563 73.49±3.390 0.075 2 98.188 .927
C20:1n9 1.151±0.042 1.207±0.056 1.409±0.123 2.099 2 62.402 .131
C22:1n9 1.792±0.241 2.042±0.317 2.010±0.652 0.219 2 1928.1 .803
C24:1n9 13.16±0.415 13.25±0.541 14.52±1.208 0.624 2 87.715 .538
C20:3n9 0.397±0.028 0.371±0.036 0.243±0.076 1.849 2 101.56 .163
Total FAs 585.5±6.571 593.3±8.685 573.3±19.72 0.527 2 984.82 .590
Abbreviations: PI, Peroxidation Index; CLI, Chain Length Index; UI Unsaturation Index; WC, Waist circumference
a N per genotype based on estimation after multiple imputation.
doi: 10.1371/journal.pone.0082980.t001
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Figure 1.  Fatty acid concentrations in recurrent depression according to FABP2 genotype.  Concentrations of four fatty acids
[eicosadienoic acid (C20:2ω6), docosadienoic acid (C22:2ω6), arachidic acid (C20:0) and gondoic acid (C20:1ω9)] in 137
recurrently depressed patients according to Ala54Thr fatty acid-binding protein 2 (FABP2) polymorphism genotype (GG, AG, AA).
doi: 10.1371/journal.pone.0082980.g001
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Figure 2.  Waist circumference according to FABP2 genotype compared between recurrently depressed patients and
healthy controls.  Waist circumference according to Ala54Thr fatty acid-binding protein 2 (FABP2) polymorphism genotype (GG,
AG, AA) in 137 recurrently depressed patients (Panel A) and 73 non-depressed controls (Panel B).
doi: 10.1371/journal.pone.0082980.g002
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(C22:2ω6) [14]. In addition, also other 20-carbon FAs (C20,
C20:2ω6, and C20:1ω9) showed a significant linear relation of
increased concentrations with one or two A-alleles.
Interestingly, previous research in healthy and CVD-subjects
did not find consistent associations of the Ala54Thr-
polymorphism with FA-concentrations [24,26,27]. This could be
explained by lack of power [24,27], use of other sample
mediums [24,26,27], lack of measurement of eicosadienoic
acid (C20:2ω6) and docosadienoic acid (C22:2ω6), or inclusion
of different patient populations [24,26,27].
Regarding other FAs, two of these previous studies found no
associations [24,26], while one other study [27] found lower
palmitoleic acid (C16:1ω7) and higher α-linolenic (C18:3ω3)
and lignoceric acid (C24:0) in phospholipids to be associated
with threonine coding FABP2-alleles. Interestingly, a study
investigating FABP2’s effect on FA-uptake suggested that
threonine coding FABP2-alleles are associated with an
increased uptake of particularly 14-18-cabon FAs, including α-
linoleic acid (C18:2ω6) [21], which can be enzymatically
elongated to eicosadienoic acid (C20:2ω6) and docosadienoic
acid (C22:2ω6) [14]. It may therefore be hypothesized that the
increased red blood cell membrane concentration of
eicosadienoic acid in our patients with the AA-genotype may
reflect an adaptive conversion of increasedly bioavailable α-
linoleic acid (C18:2ω6), to prevent accumulation of its other,
and supposedly more bioactive (as main precursor of pro-
inflammatory eicosanoids), conversion product arachidonic
acid (ARA; C20:4ω6) [14]. Of note in this respect, increased
ARA has been associated with (visceral) obesity and CVD-risk
[36,37].
Interpretation of increased eicosadienoic acid concentrations
in AA-genotype patients as an adaptive process to prevent
ARA-accumulation corresponds with the observed negative
association of eicosadienoic acid and waist circumference. In
addition, eicosadienoic acid mediated the lower waist
circumference in AA-patients: the relation between FABP2 and
waist circumference lost significance when eicosadienoic acid
was incorporated in the model. This might imply that for AA-
patients, conversion of increasedly bioavailable α-linoleic acid
(C18:2ω6) into eicosadienoic acid (C20:2ω6) instead of ARA
(C20:4ω6) helps in maintaining a low waist circumference
thereby possibly reducing CVD-risk.
4.4. Association between FABP2 and waist
circumference
Our finding of an interaction at trend level between patient-
status and FABP2-genotype on waist circumference is
intriguing. Contrary to our third hypothesis and results in
controls, AA-genotype was significantly associated with a lower
waist circumference in the MDD-patients. This may have
several explanations. First, patients’ metabolic constitution may
be influenced by other genes, e.g. mutations in the 1-carbon-
cycle, interacting with FABP2’s effect on waist circumference
[38]. In addition, stress may affect FA-metabolism leading to
different associations in patients, through the association
between the HPA-axis and FA-metabolism [39]. Finally,
FABP2’s effects may interact with dietary availability of
nutrients, which could differ between patient and controls [16].
Future research should investigate these possibilities.
Interestingly, several studies also indicate that the Ala54Thr-
polymorphism may be associated with a beneficial CVD-risk
profile in response to certain dietary regimens, including
eicosapentaenoic acid supplementation [40], or moderate-fat or
high-polyunsaturated fat diets [41,42]. In these studies,
Ala54Thr-polymorphism carriers had better metabolic
responses and e.g. a larger reduction in waist circumference.
This may indicate that different dietary preferences in patients
played a role in the interaction between patient-status and
FABP2 on waist circumference. Unfortunately, a main limitation
of the present study is that no dietary data has been collected.
Nevertheless, given the genetic nature of our observed effects,
dietary intake likely is not a confounding factor, but rather
interacts with FABP2-genotype to explain observed relations.
In addition, erythrocyte FA-concentrations are thought to be
more stable than plasma FAs, thereby reflecting long-term FA-
metabolism, instead of dietary fluctuations [17]. Future
nutrigenetic studies combining FABP2 and dietary assessment
will further elucidate their interaction in explaining altered FA-
metabolism and waist circumference in MDD(-R).
4.5. Additional limitations
Some additional limitation should be mentioned. Analyses
did not differentiate between FA-subclasses, e.g.
sphingomyelin or phosphatidylcholine. More advanced
lipidomic analyses may provide better insight into the impact of
FAB2 on FA-metabolism. However, this is the first report
including a wide range of different FAs and indices into the
analyses. This brings up another important point: the issue of
multiple testing. Because of the multitude of FAs, studying FA-
metabolism usually entails multiple comparisons. Although
often overlooked in FA-literature, multiple comparisons may
lead to type-I errors [15]. We dealt with this intrinsic problem by
(I) applying pathophysiologically driven data reduction using
the UI, CLI and PI [15], and (II) a priori designating several
outcomes as hypothesis based, and others as explorative.
However, despite these precautions, it remains important to
keep the multiple testing problem in mind when interpreting
results. None of the reported significant results would have
survived Bonferroni correction. However, this correction likely
would have been too strict considering the relatively strong
assumed correlations between the different outcomes in this
study. For that reason, strict correction in this sample could
have induced type-II errors, and therefore we consequently
chose to correct neither the results of the a priori hypothesized
outcomes, nor the explorative results, for multiple comparisons
[31]. Therefore, particularly explorative first results should be
interpreted as such, and replication in further investigations is
warranted. In addition, while power calculations showed that
we had adequate power to detect small effect sizes for almost
all analyses, we had insufficient power to detect small effect
sizes in the analyses on the differences between the different
genotype classes in FA-measures and waist circumference in
the patient group, for which we were able to detect medium
effect sizes (f>0.268). Therefore, we may have missed
additional small effects of FABP2 on FA-measures or waist
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circumference. However, for these analyses, we additionally
operationalized the effects of FABP2 as a linear function, which
resulted in adequate power to detect small effect sizes
(f2>0.080). So, in conclusion, the only effects for which our set-
up may have precluded detection of small effect sizes would be
non-linear effects of FABP2 on FA-measures and/or waist
circumference. However, both (I) existing literature on the
physiological role of FABP2, and (II) data from our sample
presented in table 1, do not suggest such non-linear
relationships.
4.6. Study strengths
Our study also has particular strengths. To our knowledge
FABP2 was investigated in a psychiatric population for the first
time, in a specific sample of MDD-R-patients with known
bimodally distributed FA-alterations. In addition, an advanced
multiple imputation procedure reduced the possibility that
missing data have influenced results [15,33]. Finally, this is the
first report of an association between FABP2 and two specific
mutually biologically related FAs, namely eicosadienoic acid
(C20:2ω6) and docosadienoic acid (C22:2ω6), which increases
knowledge on FABP2’s role in health and disease.
Conclusion
Although Ala54Thr-polymorphism distribution was not
associated with MDD, A-allele carrying patients had (I) higher
concentrations of several 20-carbon FAs, particularly
eicosadienoic acid (C20:2ω6), and associated (II) lower waist
circumference. Therefore, for AA-patients, potentially adaptive
conversion of increasedly bioavailable dietary precursors into
eicosadienoic acid might mediate maintenance of a low waist
circumference, which may guide future investigations of CVD-
prevention in these patients. Considering the explorative nature
of this first investigation of these associations, replication is
warranted, preferably by nutrigenetic studies applying
lipidomics and detailed dietary assessment.
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